{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:54:53Z","timestamp":1792691693887,"version":"4.5.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin Ltd.","doi-asserted-by":"crossref","award":["contract No.: 017926"],"award-info":[{"award-number":["contract No.: 017926"]}],"id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212354","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T19:22:15Z","timestamp":1550085735000},"page":"e0212354","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Rivaroxaban administration after acute ischemic stroke: The RELAXED study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-8355","authenticated-orcid":true,"given":"Masahiro","family":"Yasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the RELAXED study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","article-title":"Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomized controlled trials","volume":"12","author":"WN Whiteley","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","article-title":"Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials","volume":"38","author":"M Paciaroni","year":"2007","journal-title":"Stroke"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","article-title":"Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes","volume":"35","author":"L Azoulay","year":"2014","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded","volume":"163","author":"M Man-Son-Hing","year":"2003","journal-title":"Arch Intern Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"M Hori","year":"2012","journal-title":"Circ J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"JC 3rd Hemphill","year":"2015","journal-title":"Stroke"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"J Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.01.035","article-title":"Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study","volume":"25","author":"M Yasaka","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.STR.32.2.438","article-title":"Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)","volume":"32","author":"V Larrue","year":"2001","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.0000000000003283","article-title":"Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events","volume":"87","author":"DJ Seiffge","year":"2016","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ijs.12452","article-title":"Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study","volume":"10","author":"K Toyoda","year":"2015","journal-title":"Int J Stroke"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2017.2161","article-title":"Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial","volume":"74","author":"KS Hong","year":"2017","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1747493016632239","article-title":"Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study","volume":"11","author":"S Arihiro","year":"2016","journal-title":"Int J Stroke"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1253\/circj.CJ-14-0720","article-title":"Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation","volume":"78","author":"M Yasaka","year":"2014","journal-title":"Circ J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.114.005339","article-title":"Stroke prevention in Asian patients with atrial fibrillation","volume":"45","author":"M Yasaka","year":"2014","journal-title":"Stroke"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1253\/circj.CJ-13-1534","article-title":"Intracranial hemorrhage during dabigatran treatment","volume":"78","author":"M Komori","year":"2014","journal-title":"Circ J"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007034","article-title":"Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) Study","volume":"6","author":"M Paciaroni","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"T Tanigawa","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/STROKEAHA.110.589606","article-title":"Thrombolysis with 0.6 mg\/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS)","volume":"41","author":"J Nakagawara","year":"2010","journal-title":"Stroke"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study","volume":"369","author":"N Wahlgren","year":"2007","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:05:04Z","timestamp":1590015904000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212354"}},"subtitle":[],"editor":[{"given":"Tomohiko","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212354","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]}}}